Steven Gross,
Head of CellSearch Assay Development,
Menarini Silicon Biosystems, Inc.
Currently the Head of CELLSEARCH Assay Development for Menarini Silicon Biosystems and have been involved in research and development in the field of rare cell detection and analysis for most of my career. As a Scientist/Senior Scientist I have been a part of the CELLSEARCH story from its beginning at Immunicon Corporation followed by Veridex, LLC and Janssen R&D, developing the platform and the various IVD and RUO assay kits and services. I have been responsible for the build of research kits for internal and external clinical trials and have accompanied the sales and marketing teams on customer and collaboration visits to introduce the technology and act as a technical representative throughout the contracting and assay development process. Received my Master’s degree in biology from Temple University.
Redefining Circulating Tumor Cells and Enabling Liquid Biopsy. Biological and Clinical Advances Arising from the Merger of the CELLSEARCH® and DEPArray™ Technologies
Friday, 6 October 2017 at 11:00
Add to Calendar ▼2017-10-06 11:00:002017-10-06 12:00:00Europe/LondonRedefining Circulating Tumor Cells and Enabling Liquid Biopsy. Biological and Clinical Advances Arising from the Merger of the CELLSEARCH® and DEPArray™ TechnologiesLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
The prognostic power of Circulating Tumor Cells (CTC) measured using CELLSEARCH®, is arguably the most reproducible and independently verified finding in the field of CTC analysis. Evidence of different CTC populations with different clinical implications will be presented. The recent purchase of CellSearch by Menarini Silicon Biosystems serves to combine two of the most powerful automated cellular analysis platforms in the field of liquid biopsy. This combination is shedding new light on tumor heterogeneity, and its monitoring, using blood samples. It has also enabled purification of tumor cells from tissue samples of low tumor cellularity to enable CNV and NGS analysis on samples previously impossible to study. This could lead to faster outcome studies through use of banked FFPE tissue. The use of DEPArray to do complete molecular analysis on individual, or populations, of CTCs with 100% purity is now giving rise to unprecedented understanding of CTC heterogeneity, emerging CTC phenotypes, and exciting new prospects for researchers and clinicians.
Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-06 11:00:002017-10-06 12:00:00Europe/LondonRedefining Circulating Tumor Cells and Enabling Liquid Biopsy. Biological and Clinical Advances Arising from the Merger of the CELLSEARCH® and DEPArray™ TechnologiesLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
_150x75.jpg)
.gif){kind=logo}